Evidence map›Paper›PMID 40797083›Full record

ReviewJournal of cellular and molecular medicine2025

Exploring the Potential of Zein Nanoparticles in Personalised Cancer Therapy, Highlighting Their Various Methodologies, Applications and Challenges.

Hanan M Alharbi, Taha Alqahtani, Nada A Alqalawi, Shayma A Alsayegh, Basmah A Almaghrabi, Subham Sarkar, Daniel Ejim Uti, Bikram Dhara

Abstract readReview
In one paragraph

Review in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hanan M AlharbiDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Taha AlqahtaniDepartment of Pharmacology, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
Nada A AlqalawiDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Shayma A AlsayeghDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Basmah A AlmaghrabiDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Subham SarkarPostgraduate and Research Department of Biotechnology, St. Xavier's College (Autonomous), Kolkata, India.
Daniel Ejim UtiDepartment of Research Publications, Kampala International University, Kampala, Uganda.ORCID 0000-0002-1129-1785
Bikram DharaCenter for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, India.ORCID 0000-0002-5433-1994

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zein, a corn-derived prolamine protein, has become a powerful ally in the fight against cancer, particularly non-small cell lung cancer (NSCLC.) Its unique attributes, enriched by modifiable hydroxyl and amino groups, have led to the development of advanced functionalised drug delivery systems. Innovative techniques like chemical crosslinking, desolvation, dispersion and micromixing have led to the creation of zein-based nanoparticles, revolutionising cancer therapy. Central to this examination is the remarkable ability of zein NPs to enhance drug stability, optimise oral bioavailability and improve targeted drug delivery, specifically tailored to combat NSCLC. This represents not just a technological breakthrough but a paradigm shift, ushering in a new era of precise, personalised and effective cancer treatment. Zein, a hydrophobic nanoparticle, is a promising drug for cancer treatment. However, its journey to the clinic is challenging due to its hydrophobic nature and the need for advanced evaluative platforms. This review emphasises the need for rigorous research to align zein's potential with real-world applications. It offers a synthesis of methodologies, applications, and obstacles, aiming to see zein nanoparticles as a central element in cancer therapy innovations. The review encourages researchers, clinicians and industry professionals to embrace the potential of zein and promote the convergence of laboratory innovation and clinical application.

Indexed as

Antineoplastic AgentsNanoparticlesNeoplasmsPrecision MedicineZeinAnimalsDrug CarriersDrug Delivery SystemsHumansAntineoplastic AgentsDrug CarriersZeinadvanced drug delivery mechanismscancer therapyoral bioavailabilityprecision medicinezein nanoparticles

Identifiers

PMID40797083
PMCPMC12343330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.